Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid
Tiered Pricing To Allow Equitable Access
Executive Summary
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.
You may also be interested in...
Will Pfizer's Paxlovid Go The Lagevrio Way In India?
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Coronavirus Notebook: UK Sets Up ‘Pioneering’ Vaccines Lab, MSF Piles Pressure On TRIPS Waiver Holdouts
The UK has OKd trials of a new AI-derived combination treatment from Canadian firm Skymount Medical. Health Canada has approved Novavax’s COVID-19 vaccine, and Australia has given the go-ahead to use Moderna’s Spikevax in children aged six years and up.
Yes We Can: South African Scientists On Their Way With mRNA Vaccine
South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.